Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 23, 2026

1 Unstoppable Cryptocurrency to Buy Before It Soars 930%, According to Cathie Wood's Ark Invest

View original at nasdaq.com
1 Unstoppable Cryptocurrency to Buy Before It Soars 930%, According to Cathie Wood's Ark Invest Key Points Bitcoin boasts a market capitalization of around $1.5 trillion, making it the world's largest cryptocurrency…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • When gold surged 64% in 2025 due to soaring U.S. government spending and Trump tariff uncertainty, investors chose gold over Bitcoin as their preferred safe-haven asset, representing a flaw in Ark's digital gold thesis.

    60% confidence
  • Bitcoin was not among the 10 best stocks for investors to buy now, according to the Motley Fool Stock Advisor analyst team.

    60% confidence
  • Bitcoin on-chain financial services, enabling peer-to-peer transactions bypassing traditional banks, represent a significant upside catalyst for Bitcoin's valuation by 2030.

    60% confidence
  • Most of the capital inflows into digital assets in Q1 2026 coming from a single buyer (Strategy) is not a recipe for sustainable Bitcoin upside.

    60% confidence
  • Ark's prediction that global fund managers will eventually park up to 6.5% of their managed assets in Bitcoin might be too optimistic, and a very low probability should be assigned to Ark's target of $800,000 per coin.

    60% confidence
  • Investors are on track to deploy around $44 billion in fresh capital into digital assets in 2026, approximately one-third of the amount deployed in 2025.

    60% confidence
  • A $16 trillion Bitcoin market cap would be more than three times as valuable as Nvidia, the world's largest company at $5.3 trillion, and would represent roughly half of U.S. annual GDP of $30.7 trillion.

    60% confidence
  • Bitcoin could amass up to 60% of gold's $31 trillion market cap as investors seek a digital alternative to physical gold.

    60% confidence
  • Bitcoin could reach a $16 trillion market capitalization by 2030, implying a price of approximately $800,000 per coin, representing 930% upside from ~$77,700.

    60% confidence
  • Companies could add Bitcoin to their balance sheets as a hedge against inflation and economic uncertainty, as it is often impractical to own physical gold.

    60% confidence
  • Citizens in developing countries will increasingly buy Bitcoin as a hedge against economic and political turmoil, though this opportunity was reduced in the 2026 report due to stablecoin competition.

    60% confidence
  • Demand from retail and institutional investors into digital assets was extremely small or potentially even negative in Q1 2026, with most capital inflows coming from a single buyer: Strategy (Michael Saylor's Bitcoin treasury company).

    60% confidence
  • Global governments will eventually hold some Bitcoin in reserve, similar to how they hold gold and other strategic assets.

    60% confidence
  • Global fund managers could allocate up to 6.5% of their $200 trillion in managed assets into Bitcoin as an institutional investment.

    60% confidence

Data points we hold from this source

Bitcoin · circulating supply20000000 coins
Bitcoin · market share50 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com